Understanding how a specific protein modification affects cancer treatment in colorectal cancer.
Investigating the role of neddylation in the repair of topoisomerase I inhibitor-induced replication damage in colorectal cancer
['FUNDING_OTHER'] · UNIVERSITY OF MARYLAND BALTIMORE · NIH-11241179
This study is looking at how a process called neddylation helps fix DNA damage caused by certain cancer treatments, like irinotecan, which are often used for colorectal cancer, with the hope of finding better ways to make these treatments work even better for patients.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF MARYLAND BALTIMORE (nih funded) |
| Locations | 1 site (BALTIMORE, UNITED STATES) |
| Trial ID | NIH-11241179 on ClinicalTrials.gov |
What this research studies
This research investigates the role of neddylation, a protein modification process, in repairing DNA damage caused by topoisomerase I inhibitors, which are commonly used to treat colorectal cancer. The study aims to understand how this process affects the effectiveness of chemotherapy drugs like irinotecan. By exploring the mechanisms of DNA repair and the potential to enhance the efficacy of these treatments, the research could lead to improved therapeutic strategies for patients. The approach includes high-throughput screening of cancer cells and examining the interactions between proteins involved in DNA repair.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with colorectal cancer who are undergoing treatment with topoisomerase I inhibitors.
Not a fit: Patients with colorectal cancer who are not receiving topoisomerase I inhibitors or those with other types of cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for colorectal cancer, improving patient outcomes.
How similar studies have performed: Previous research has shown promising results in targeting DNA repair mechanisms to enhance the efficacy of cancer treatments, suggesting that this approach could be beneficial.
Where this research is happening
BALTIMORE, UNITED STATES
- UNIVERSITY OF MARYLAND BALTIMORE — BALTIMORE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SUN, YILUN — UNIVERSITY OF MARYLAND BALTIMORE
- Study coordinator: SUN, YILUN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Anti-Cancer Agents, anti-cancer drug